Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Jul 11, 2020
Date Accepted: Mar 24, 2021
Date Submitted to PubMed: May 3, 2021
SARS-COV-2: THE SECOND WAVE IN EUROPE
ABSTRACT
Although the SARS CoV-2 virus has already undergone several mutations, the impact of these mutations on infectivity and virulence remains controversial. In this viewpoint we present arguments suggesting less virulence but much higher infectivity. This suggestion is based on the results of the forecasting and mechanistic models developed by our group. In particular, the analysis of our mechanistic model predicted in May 2020, that the easing of the lockdown measures will lead to a dramatic ‘second wave’. However, after the lifting of the lockdown in many European counties, the resulting number of reported infected and especially the number of deaths remained small for approximately two months. This raised the false hope that a substantial ‘second wave’ will be avoided and that the Covid-19 epidemics in these European countries was coming to an end. Unfortunately, since the first week of August,2020, the number of reported infected increased dramatically. Furthermore, this was accompanied by an increasingly large number of deaths. The rate of reported infected in the second wave was much higher than the first wave, whilst the rate of deaths was lower. This is consistent with higher infectivity and lower virulence. Even if the mutated form is less virulent, the very high number of reported infected implies that a large number of people will perish.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.